FKBP1A binds FKBP1A inhibitors

Stable Identifier
R-HSA-9679044
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Sirolimus and tacrolimus are macrolide compounds obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. They are bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, peptidyl-prolyl cis-trans isomerase (FKBP1A, FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP1A complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP1A, creating a new complex. This complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription (Kino et al. 1987, Ding et al. 2019).

Literature References
PubMed ID Title Journal Year
30294901 Rapamycin and FK506 derivative TH2849 could ameliorate neurodegenerative diseases through autophagy with low immunosuppressive effect

Ding, L, Nan, WH, Zhu, XB, Li, XM, Zhou, LY, Chen, HJ, Yu, L, Ullah Khan, F, Zhong, HB, Shi, XJ

CNS Neurosci Ther 2019
2445721 FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

Kino, T, Hatanaka, H, Hashimoto, M, Nishiyama, M, Goto, T, Okuhara, M, Kohsaka, M, Aoki, H, Imanaka, H

J. Antibiot. 1987
9857082 Immunophilins: beyond immunosuppression

Hamilton, GS, Steiner, JP

J. Med. Chem. 1998
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!